APL with Sanz intermediate risk — WBC ≤10 ×10^9/L AND platelets ≤40 ×10^9/L — eligible fo...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-SANZ-INTERMEDIATE`
Type	Red flag
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-APL`
Sources	`SRC-APL0406-LOCOCO-2013` `SRC-ELN-APL-2019` `SRC-NCCN-AML-2025`

Red Flag Origin

Definition	APL with Sanz intermediate risk — WBC ≤10 ×10^9/L AND platelets ≤40 ×10^9/L — eligible for ATRA+ATO chemo-free per APL0406; some protocols add limited anthracycline (idarubicin) per AIDA-style backbone
Clinical direction	investigate
Category	risk-score

Trigger Logic

{
  "all_of": [
    {
      "comparator": "<=",
      "finding": "wbc_count_x10_9_per_l",
      "threshold": 10
    },
    {
      "comparator": "<=",
      "finding": "platelet_count_x10_9_per_l",
      "threshold": 40
    }
  ],
  "type": "composite_score"
}

Notes

Sanz intermediate — same induction outcome category as low-risk in APL0406 (combined non-high-risk arm). Both groups treated with ATRA+ATO chemo-free. ELN-APL 2019 allows anthracycline addition for intermediate-risk if platelets very low or in resource-limited settings. Direction `investigate` because the score alone does not flip the indication — the algorithm picks ATRA+ATO unless the high-risk flag fires; this RF surfaces the cohort for MDT brief.

Used By

Algorithms

ALGO-APL-1L - ALGO-APL-1L